Oncogenes: Understanding Cancer-Causing Genes

Oncogenes are mutated versions of normal genes (proto-oncogenes) that drive uncontrolled cell growth and division, leading to cancer. When activated, they signal cells to reproduce incessantly—essentially stuck in the "on" position.

From Proto-oncogene to Oncogene

• Proto-oncogenes: Normal genes regulating cell proliferation, differentiation, and survival (e.g., growth factors, receptors, signal transducers, transcription factors).
• Activation mechanisms: Point mutations, gene amplification, chromosomal translocation, viral insertion.
• Result: Gain-of-function—excessive or constitutive signaling.

Classic Examples

• RAS family (HRAS, KRAS, NRAS): Mutated in ~30% of all cancers (pancreas, colon, lung).
• MYC: Amplified in many cancers (Burkitt lymphoma, breast, lung).
• EGFR/HER2: Overexpressed/mutated in lung, breast, glioblastoma.
• BCR-ABL fusion (Philadelphia chromosome): Drives chronic myeloid leukemia (CML).

Contrast with Tumor Suppressor Genes

Tumor suppressors (e.g., TP53, RB1, PTEN) normally restrain growth. Their loss-of-function (both alleles inactivated) permits cancer. Oncogenes require only one activated allele (dominant).

Therapeutic Targeting

• Tyrosine kinase inhibitors (imatinib for BCR-ABL, erlotinib for EGFR).
• Monoclonal antibodies (trastuzumab for HER2).
• Downstream pathway inhibitors (MEK, mTOR inhibitors).
• Precision oncology matches drugs to specific oncogenic drivers.

Key Takeaway

Oncogenes are mutated genes that signal cells to reproduce uncontrollably. Their discovery revolutionized cancer biology and enabled targeted therapies that improve survival for many malignancies.